Novartis Kisqali^® Reports Longest Median Overall Survival in Postmenopausal HR⁺/HER2^– Metastatic Breast Cancer Patients

Novartis announced updated median overall survival (OS) results for Kisqali® in combination with fulvestrant in postmenopausal women with HR+/HER2– metastatic breast cancer. This combination demonstrated a clinically relevant OS benefit of more than a year compared with fulvestrant alone.